Feed HEPA
HE

Hepion Pharmaceuticals, Inc.

HEPA · OTC

$0.08 +7.18% (+$0.01)
1M +26.07%
Market Cap $835.4K
P/E Ratio -
Div. Yield -
ROE 139.73%
Piotroski F-Score Weak
1/9
Valuation
100 /100
Cheap
P/B 0.65x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining
Book val. growth 62.32%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor
ROIC 219.39%
Asset turnover 0.00x
ROE 139.73%
Debt
69 /100
Low
Debt/Equity 0.00x
Int. coverage -124.87x
Current ratio 3.91x
Stability
19 /100
Unstable
Beta 1.76x
Profitable years 0
EPS volatility 55.17%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o HEPA
Online

O podjetju

Hepion Pharmaceuticals, Inc. (HEPA) is a biotechnology company focused on the research and development of therapies for liver diseases and metabolic disorders. Headquartered in the United States, the company aims to utilize its drug candidates to treat diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepion Pharmaceuticals seeks to develop innovative pharmaceutical solutions for patients with these serious health conditions. Shares of Hepion Pharmaceuticals, Inc. (HEPA), listed on the NASDAQ, can be an appealing choice for investors seeking investment opportunities in the biotechnology and liver disease treatment sector.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Gary S. Stetz

Employees

2

Headquarters

Morristown

Prihajajoči dogodki

14 OKT.

Earnings

Upcoming earnings report

25d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.